Searched for
MRNA STOCKS
Moderna stocks: MRNA shares jump in US Stock market today after pharma giant surpasses Wall Street estimatesModerna had earlier posted a loss of $2.52 per share a year earlier, while analysts expected a loss of $3.96 per share.- US Stocks: Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhangModerna shares rose 9% on Wednesday after it settled a long-running legal battle over the technology that made its COVID-19 vaccine possibl...
- RFK Jr. shocks big pharma, yanks $500 million from mRNA vaccine projects, including for Flu and COVIDUS Health Secretary Robert F. Kennedy Jr. stopped 22 vaccine projects. These projects used mRNA technology. The vaccines aimed to fight COV...
- Moderna plans to lay off 10% of workforce to cut costsModerna is set to reduce its global workforce by roughly 10%, aiming for under 5,000 employees by year's end, as it accelerates cost-cuttin...
- Moderna layoffs: U.S. Pharma giant announces massive job cuts, to have less than 5,000 employees, MRNA stocks sinkModerna had said earlier this year it expects operating costs to be between $4.7 billion and $5 billion for 2027. MRNA stock, which has los...
- Over 200m doses of Covaxin set to expireMillions of doses of Covaxin are set to expire early next year and may have to be dumped amid poor demand for Covid-19 vaccination in the c...
- You may not get a booster shot at most private facilitiesMost private hospital executives ET spoke with said they had stopped procuring Covid vaccines due to tepid demand. The Max Healthcare hospi...
- AstraZeneca jab uncertainty will hit Oxford BioMedica’s revenueIn a recent report, Oxford Biomedica warned that uncertainty surrounding AstraZeneca’s Covid-19 contract will bring reduction in earnings t...
- Moderna finds that inventing a COVID-19 vaccine was the easy partModerna shares plummeted on Thursday after it announced it would be able to supply only 700 million to 800 million vaccine doses this year,...
- Chinese firm buys Canada mRNA Covid vaccine tech in $500 million dealWhile almost 1 billion people have been fully vaccinated in China, the country is still lacking an mRNA shot, with most of the population i...
- China shares fall as weak lending data fans liquidity concernsThe blue-chip CSI300 index fell 0.8%, to 4,973.35, while the Shanghai Composite Index lost 0.2% to 3,524.74 points.
- Nothing commercial yet on Moderna’s vaccine in India: Kedar Upadhye, Cipla CFOIt did well. During the pandemic, it was the responsibility of the industry to do what one can to service. Parallelly, all life-saving medi...
- Not in talks with local companies to make vaccine in India: PfizerVarious governments, WHO and others have been pushing vaccine makers to transfer technology to companies in Asia and Africa to scale up pro...
- Countries seek more Moderna, Pfizer/BioNTech shots as concerns mount over rival vaccinesCountries in Europe and Asia, as well as South Africa, are limiting or halting use of AstraZeneca's shot over safety concerns. Rollout of J...
- Moderna mania draws bitcoin comparisons while shorts bleedModerna jumped as much as 17% in New York Tuesday. The stock has surged about 73% and added more than $28 billion in market value over the ...
- States told to prioritise groups for vaccinationThe ministry has also developed digital content to train and orient vaccinators, detailing how they should administer the vaccine and how t...
- Protein-based COVID-19 vaccine candidates would be more suitable for India, scientists sayThe decision on procuring the right COVID-19 vaccine depends on multiple factors, including safety, price and ease of deployment, the scien...
- EU talks with Pfizer, Sanofi, J&J on COVID-19 vaccines hit pricing, payment roadblocksThe bloc is in talks with at least six vaccine makers to acquire up front doses of potential shots against the novel coronavirus, officials...
- Wipro founder Azim Premji is an early investor in US firm ModernaWipro founder Azim Premji is an investor in Moderna, the firm that has emerged a frontrunner for Covid vaccine.
- US drugmaker reports promising early results from COVID-19 vaccine testThe Cambridge, Massachusetts-based company said the vaccine candidate, mRNA-1273, appeared to produce an immune response in eight people wh...
Load More
